Evidence map›Paper›PMID 27618820›Full record

ArticleCancer research and treatment2017

Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea.

Gebra Cuyun Carter, Anna Kaltenboeck, Jasmina Ivanova, Astra M Liepa, Alexandra San Roman, Maria Koh, Narayan Rajan, Rebecca Cheng, Howard G Birnbaum, Jong Seok Kim and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Current therapeutic options for gastric adenocarcinoma.Saudi journal of biological sciences · 2021
    Review
  9. Article
  10. Article
  11. Observational
  12. Observational
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Gebra Cuyun CarterEli Lilly and Company, Indianapolis, IN, USA.
Anna KaltenboeckAnalysis Group, New York, NY, USA.
Jasmina IvanovaAnalysis Group, New York, NY, USA.
Astra M LiepaEli Lilly and Company, Indianapolis, IN, USA.
Alexandra San RomanAnalysis Group, Boston, MA, USA.
Maria KohAnalysis Group, New York, NY, USA.
Narayan RajanEli Lilly and Company, Sydney, Australia.
Rebecca ChengEli Lilly and Company, Taipei, Taiwan.
Howard G BirnbaumAnalysis Group, Boston, MA, USA.
Jong Seok KimEli Lilly and Company, Seoul, Korea.
Yung-Jue BangDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Analysis Group (United States) · USEli Lilly (United States) · USSeoul National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study was to understand patient treatment patterns, outcomes, and healthcare resource use in cases of metastatic and/or locally recurrent, unresectable gastric cancer (MGC) in South Korea. MATERIALS AND

methodsThirty physicians reviewed charts of eligible patients to collect de-identified data. Patients must have received platinum/fluoropyrimidine first-line therapy followed by second-line therapy or best supportive care, had no other primary cancer, and not participated in a clinical trial following MGC diagnosis. Data were summarized using descriptive statistics. Kaplan-Meier analysis was used to describe survival.

resultsOf 198 patients, 73.7% were male, 78.3% were diagnosed with MGC after age 55 (mean, 61.3 years), and 47.0% were current or former smokers. The majority of tumorswere located in the antrum/pylorus (51.5%). Metastatic sites most often occurred in the peritoneum (53.5%), lymph nodes (47.5%), and liver (38.9%). At diagnosis, the mean Charlson comorbidity indexwas 0.4 (standard deviation, 0.6). The most common comorbidities were chronic gastritis (22.7%) and cardiovascular disease (18.7%). Most patients (80.3%) received second-line treatment. Single-agent fluoropyrimidine was reported for 22.0% of patients, while 19.5% were treated with irinotecan and a fluoropyrimidine or platinum agent. The most common physician-reported symptoms during second-line treatment were nausea/vomiting (44.7%) and pain (11.3%), with antiemetics (44.7%), analgesics (36.5%), and nutritional support (11.3%) most often used as supportive care. Two-thirds of inpatient hospitalizations were for chemotherapy infusion. Outpatient hospitalization (31.6%) and visits to the oncologist (58.8%) were common among second-line patients.

conclusionMost patients received second-line treatment, although regimens varied. Understanding MGC patient characteristics and treatment patterns in South Korea will help address unmet needs.

Indexed as

Practice Patterns, Physicians'AdultAgedAged, 80 and overCombined Modality TherapyComorbidityDisease ManagementDisease ProgressionFemaleHealth Services AccessibilityHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingObservational studyRepublic of KoreaResource useStomach neoplasmsTreatment patterns

Identifiers

PMID27618820
PMCPMC5512370
OpenAlexW2520172708

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.